3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
28
Lymphoma
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Breast Neoplasms
22
Multiple Myeloma
21
Lymphoma, Large B-Cell, Diffuse
21
Carcinoma, Non-Small-Cell Lung
21
Lymphoma, Non-Hodgkin
19
Lymphoma, Mantle-Cell
17
Lymphoma, Follicular
16
Hodgkin Disease
15
Lymphoma, T-Cell, Cutaneous
13
Glioblastoma
13
Leukemia, Lymphocytic, Chronic, B-Cell
12
Brain Neoplasms
12
Recurrence
11
Myelodysplastic Syndromes
11
Mycosis Fungoides
11
Lymphoma, B-Cell, Marginal Zone
11
Leukemia
11
Burkitt Lymphoma
11
Neuroblastoma
10
Neoplasms
10
Sezary Syndrome
9
Congenital Abnormalities
9
Prostatic Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
8
Squamous Cell Carcinoma of Head and Neck
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms, Plasma Cell
7
Interventions
pembrolizumab
9
Cisplatin
9
Cetuximab
6
Paclitaxel
5
Radiotherapy
4
Fluorouracil
4
zalutumumab
3
Nivolumab
3
Docetaxel
3
Taxes
2
Radiotherapy, Intensity-Modulated
2
Pemetrexed
2
Gefitinib
2
Cyclophosphamide
2
Carboplatin
2
temsirolimus
1
sintilimab
1
poly ICLC
1
osimertinib
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
durvalumab
1
cobimetinib
1
atezolizumab
1
advexin
1
abemaciclib
1
Vorinostat
1
Sorafenib
1
Risk Factors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Squamous Cell
×
Vorinostat
×
Clear all
NCT04357873
2025-02-19
PEVOsq
UNICANCER
Phase 2
Completed
112 enrolled